Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-101, Nivolumab, and Ipilimumab in Advanced EP-NECAs
NCT05262556Phase 1Completed
- Start
- Dec 2022
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pritumumab in neuroendocrine carcinoma (NEC). Primary endpoint: Antitumor activity up to 6 months. Started Dec 2022; status: completed.
02
Drugs
pritumumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05262556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262556.